4,541 results match your criteria Headache Cluster

Oxygen Therapy in Cluster Headache, Migraine, and Other Headache Disorders.

J Clin Neurol 2022 May;18(3):271-279

Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.

Oxygen therapy (OT) can relieve head pain in certain primary headache disorders, including cluster headache (CH). The exact underlying mechanism is currently uncertain, but suggested mechanisms include inhibition of the trigeminoautonomic reflex, modulation of neurotransmitters, and cerebral vasoconstriction. OT is the standard for acute treatment of CH, but patients with CH often experience considerable difficulties accessing home OT due to problems with insurance coverage. Read More

View Article and Full-Text PDF

Glymphatic system dysfunction in patients with cluster headache.

Brain Behav 2022 May 17:e2631. Epub 2022 May 17.

Department of Neurology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.

Introduction: The aim of this study was to investigate alterations of the glymphatic system function in patients with cluster headache.

Methods: We enrolled patients with cluster headache and healthy controls, and they underwent brain magnetic resonance imaging (MRI), including diffusion tensor imaging (DTI). We used the MRIcron and DSI studio programs for DTI preprocessing and DTI analysis with perivascular space (DTI-ALPS) index calculation. Read More

View Article and Full-Text PDF

Psychedelics in the Treatment of Headache and Chronic Pain Disorders.

Curr Top Behav Neurosci 2022 May 12. Epub 2022 May 12.

Headache Center of Excellence, Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA.

The therapeutic potential of psychedelics in headache and chronic pain disorders is documented over decades of anecdotal and early investigational reports, which have paved the way for the first controlled studies of psilocybin and lysergic acid diethylamide (LSD) in these disorders. The reported lasting clinical effects after limited dosing with psychedelics present a novel means for disease management, but considerable further study will be required to address disease-specific treatments, uncover mechanism(s) of action, and verify safety. In this chapter, these topics are reviewed with particular attention to the neurobiological systems that offer potential sources of psychedelics' unique clinical effects in headache and pain. Read More

View Article and Full-Text PDF

The nocebo response in pharmacologic treatments of primary headache: a systematic review and meta-analysis.

J Clin Pharmacol 2022 May 9. Epub 2022 May 9.

Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, 430060, China.

The nature and magnitude of nocebo responses in primary headache disorders are still unknown. To assess the distribution and possible predictors of nocebo responses in primary headache treatments, databases including PubMed, EMBASE, and Cochrane Library were searched from 1988 to 31 December 2020 for parallel-group, double-blind, randomised placebo-controlled trials (RCTs) of pharmacologic treatments of primary headaches. The nocebo responses were calculated using a random effects meta-analysis model. Read More

View Article and Full-Text PDF

[Galcanezumab for episodic and chronic cluster headache].

Schmerz 2022 Apr 27. Epub 2022 Apr 27.

Kopfschmerzzentrum Frankfurt, Dalbergstraße 2a, 65929, Frankfurt am Main, Deutschland.

Background: Cluster headache (CH) is a highly debilitating headache disorder characterized by frequent attacks of excruciating unilateral pain accompanied by cranial autonomic symptoms. Calcitonin gene-related peptide (CGRP) is implicated in the pathophysiology of CH.

Objectives: Preventive efficacy and tolerability of the anti-CGRP antibody galcanezumab in patients with episodic (eCH) and chronic CH (cCH). Read More

View Article and Full-Text PDF

Phosphatidylethanolamine Deficiency and Triglyceride Overload in Perilesional Cortex Contribute to Non-Goal-Directed Hyperactivity after Traumatic Brain Injury in Mice.

Biomedicines 2022 Apr 15;10(4). Epub 2022 Apr 15.

Institute of Clinical Pharmacology, Medical Faculty, Goethe-University, 60590 Frankfurt, Germany.

Traumatic brain injury (TBI) is often complicated by long-lasting disabilities, including headache, fatigue, insomnia, hyperactivity, and cognitive deficits. In a previous study in mice, we showed that persistent non-goal-directed hyperactivity is a characteristic post-TBI behavior that was associated with low levels of endocannabinoids in the perilesional cortex. We now analyzed lipidome patterns in the brain and plasma in TBI versus sham mice in association with key behavioral parameters and endocannabinoids. Read More

View Article and Full-Text PDF

Current practice for primary headache disorders and perspectives on peripheral nerve blocks among emergency physicians in Canada: A national survey.

Headache 2022 04 10;62(4):512-521. Epub 2022 Apr 10.

School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.

Objective: This national postal survey aimed to examine Canadian emergency physicians' practice patterns with respect to drug treatment and perspectives on peripheral nerve blocks.

Background: The treatment of primary headache disorders in the emergency department is variable.

Methods: We surveyed 500 emergency physicians listed in the Canadian Medical Directory according to a modified Dillman's method: an initial invitation was followed by up to four reminders to nonresponders. Read More

View Article and Full-Text PDF

Alterations of thalamic nuclei volumes in patients with cluster headache.

Neuroradiology 2022 Apr 11. Epub 2022 Apr 11.

Departments of Neurology, Haeundae Paik Hospital, Inje University College of Medicine, Haeundae-ro 875, Haeundae-gu, Busan, 48108, Korea.

Purpose: This study aimed to compare the alterations of thalamic nuclei volumes and the intrinsic thalamic network in patients with cluster headache and healthy controls.

Methods: We retrospectively enrolled 24 patients with episodic cluster headache and 24 healthy controls. We calculated the thalamic nuclei volumes in the patients with cluster headache and healthy controls based on three-dimensional T1-weighted imaging with automated segmentation using the FreeSurfer program. Read More

View Article and Full-Text PDF

Challenges and complexities in designing cluster headache prevention clinical trials: A narrative review.

Headache 2022 04 1;62(4):453-472. Epub 2022 Apr 1.

Eli Lilly and Company, Indianapolis, Indiana, USA.

Objective: To provide a review of challenges in clinical trials for the preventive treatment of cluster headache (CH) and highlight considerations for future studies.

Background: Current guidelines for preventive treatment of CH are largely based on off-label therapies supported by a limited number of small randomized controlled trials. Guidelines for clinical trial design for CH treatments from the International Headache Society were last issued in 1995. Read More

View Article and Full-Text PDF

mBrain: towards the continuous follow-up and headache classification of primary headache disorder patients.

BMC Med Inform Decis Mak 2022 Mar 31;22(1):87. Epub 2022 Mar 31.

IDLab, Ghent University - imec, 9052, Ghent, Belgium.

Background: The diagnosis of headache disorders relies on the correct classification of individual headache attacks. Currently, this is mainly done by clinicians in a clinical setting, which is dependent on subjective self-reported input from patients. Existing classification apps also rely on self-reported information and lack validation. Read More

View Article and Full-Text PDF

Intravenous Lidocaine and Ketamine Infusions for Headache Disorders: A Retrospective Cohort Study.

Front Neurol 2022 9;13:842082. Epub 2022 Mar 9.

Department of Neurology, Alfred Hospital, Melbourne, VIC, Australia.

Introduction: The use of lidocaine (lignocaine) and ketamine infusion in the inpatient treatment of patients with headache disorders is supported by small case series. We undertook a retrospective cohort study in order to assess the efficacy, duration and safety of lidocaine and ketamine infusions.

Methods: Patients admitted between 01/01/2018 and 31/07/2021 were identified by ICD code and electronic prescription. Read More

View Article and Full-Text PDF

Network meta-analysis of therapies for cluster headache: Effects of acute therapies for episodic and chronic cluster.

Headache 2022 04 28;62(4):482-511. Epub 2022 Mar 28.

University of Ottawa, Ottawa, Ontario, Canada.

Objective: We used network meta-analysis (NMA) to characterize the relative effectiveness and harms of acute treatment options for cluster headache.

Background: There are few evidence-based acute treatments available for cluster headache. As most treatments were compared only against placebos in clinical trials, few head-to-head comparisons of treatments are available. Read More

View Article and Full-Text PDF

Effects of acute and preventive therapies for episodic and chronic cluster headache: A scoping review of the literature.

Headache 2022 Mar;62(3):329-362

University of Ottawa, Ottawa, Ontario, Canada.

Background: Cluster headache is the most common primary headache disorder of the trigeminal autonomic cephalalgias, and it is highly disabling.

Objective: We undertake a scoping review to characterize therapies to prevent and acutely treat cluster headache, characterize trial methodology utilized in studies, and recommend future trial "good practices." We also assess homogeneity of studies and feasibility for future network meta-analyses (NMAs) to compare acute and preventive treatments for cluster headache. Read More

View Article and Full-Text PDF

Cluster headache pathophysiology: What we have learned from advanced neuroimaging.

Headache 2022 04 21;62(4):436-452. Epub 2022 Mar 21.

Headache Centre, Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.

Background: Although remarkable progress has been achieved in understanding cluster headache (CH) pathophysiology, there are still several gaps about the mechanisms through which independent subcortical and cortical brain structures interact with each other. These gaps could be partially elucidated by structural and functional advanced neuroimaging investigations.

Objective: Although we are aware that substantial achievements have come from preclinical, neurophysiological, and biochemical experiments, the present narrative review aims to summarize the most significant findings from structural, microstructural, and functional neuroimaging investigations, as well as the consequent progresses in understanding CH pathophysiological mechanisms, to achieve a comprehensive and unifying model. Read More

View Article and Full-Text PDF

Paroxysmal hemicrania or short-lasting unilateral neuralgiform headache attacks with trigeminal neuralgia - functional neuroimaging findings.

Neurol Neurochir Pol 2022 Mar 21. Epub 2022 Mar 21.

Warsaw University of Technology, Faculty of Electronics and Information Technology, The Institute of Radioelectronics and Multimedia Technology, Warsaw, Poland.

View Article and Full-Text PDF

Multimodal ayurvedic approach in the management of moderate SARS-COV2 infection with co-morbidities - A case report.

J Family Med Prim Care 2022 Jan 31;11(1):344-349. Epub 2022 Jan 31.

Department of Kayachikitsa, All India Institute of Ayurveda, New Delhi, India.

Introduction: The World Health Organization (WHO) declared COVID-19 a pandemic which has claimed more than 1.4 million lives as of today. This unprecedented period demands greatly for the traditional and native medical systems which are time-tested and holistic. Read More

View Article and Full-Text PDF
January 2022

Cluster Headache Impact Questionnaire (CHIQ) - a short measure of cluster headache related disability.

J Headache Pain 2022 Mar 18;23(1):37. Epub 2022 Mar 18.

Department of Neurology, University Hospital, Ludwig-Maximilians-University (LMU), Munich, Germany.

Background: Cluster headache (CH) is a severe, highly disabling primary headache disorder. However, there is little research on CH-related disability, and most of it is based on non CH-specific questionnaires. The aim of this study was to develop a short, CH-specific disability questionnaire. Read More

View Article and Full-Text PDF

Unilateral increased visual sensitivity in cluster headache: a cross-sectional study.

Cephalalgia 2022 Mar 18:3331024221077664. Epub 2022 Mar 18.

Department of Neurology, 4501Leiden University Medical Center, Leiden University Medical Center, Leiden, the Netherlands.

Background And Objectives: Increased sensitivity to light and patterns is typically associated with migraine, but has also been anecdotally reported in cluster headache, leading to diagnostic confusion. We wanted to assess whether visual sensitivity is increased ictally and interictally in cluster headache.

Methods: We used the validated Leiden Visual Sensitivity Scale (L-VISS) questionnaire (range 0-36 points) to measure visual sensitivity in people with episodic or chronic cluster headache: (i) during attacks; (ii) in-between attacks; and in episodic cluster headache (iii) in-between bouts. Read More

View Article and Full-Text PDF

[Trigeminal Autonomic Cephalgias].

Fortschr Neurol Psychiatr 2022 Mar 16;90(3):121-134. Epub 2022 Mar 16.

Compared with migraine and tension-type headache, trigeminal autonomic cephalgias (TAC) are rare, but the resulting significant impairment and the not irrelevant prevalence (e. g., cluster headache 0. Read More

View Article and Full-Text PDF

Intranasal treatment of cluster headache: A response.

Headache 2022 03 16;62(3):396-397. Epub 2022 Mar 16.

Danish Headache Center, Department of Neurology, Rigshospitalet- Glostrup, Glostrup, Denmark.

View Article and Full-Text PDF

Two-month follow-up of persons with SARS-CoV-2 infection-Zambia, September 2020: a cohort study.

Pan Afr Med J 2022 11;41:26. Epub 2022 Jan 11.

Department of Infectious Disease and Control, University Teaching Hospital, Lusaka, Zambia.

Introduction: COVID-19 is often characterized by an acute upper respiratory tract infection. However, information on longer-term clinical sequelae following acute COVID-19 is emerging. We followed a group of persons with COVID-19 in Zambia at two months to assess persistent symptoms. Read More

View Article and Full-Text PDF

Paediatric post-concussive symptoms: symptom clusters and clinical phenotypes.

Br J Sports Med 2022 Mar 10. Epub 2022 Mar 10.

Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.

Objective: To assess the co-occurrence and clustering of post-concussive symptoms in children, and to identify distinct patient phenotypes based on symptom type and severity.

Methods: We performed a secondary analysis of the prospective, multicentre Predicting and Preventing Post-concussive Problems in Pediatrics (5P) cohort study, evaluating children 5-17 years of age presenting within 48 hours of an acute concussion. Our primary outcome was the simultaneous occurrence of two or more persistent post-concussive symptoms on the Post-Concussion Symptom Inventory at 28 days post-injury. Read More

View Article and Full-Text PDF

[Sphenopalatine ganglion stimulation in the treatment of chronic refractory cluster headache. A preliminary multicenter study in Russia].

Zh Nevrol Psikhiatr Im S S Korsakova 2022 ;122(2):68-73

City Clinical Hospital No. 52, Moscow, Russia.

Objective: To analyze the results of sphenopalatine ganglion stimulation in treatment of chronic headache.

Materials And Methods: Medical histories of patients who underwent sphenopalatine ganglion stimulation in 4 clinical centers have been analyzed. The analysis included the type of pain and its characteristics, methods of surgery, CT, MRI, radiography before and after surgery. Read More

View Article and Full-Text PDF

Comparative Impact of Pharmacological Therapies on Cluster Headache Management: A Systematic Review and Network Meta-Analysis.

J Clin Med 2022 Mar 4;11(5). Epub 2022 Mar 4.

Department of Clinical Medicinal Sciences, Konyang University, Nonsan 32992, Korea.

It is important to find effective and safe pharmacological options for managing cluster headache (CH) because there is limited evidence from studies supporting the general efficacy and safety of pharmacological therapies. This systematic review and network meta-analysis (NMA) analyzed published randomized controlled trials (RCTs) to evaluate the efficacy and safety of pharmacological treatments in patients with CH. The PubMed and Embase databases were searched to identify RCTs that evaluated the efficacy and safety of pharmacological treatments for CH. Read More

View Article and Full-Text PDF

Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms.

Open Forum Infect Dis 2022 Apr 7;9(4):ofac060. Epub 2022 Mar 7.

Centre for Experimental Pathogen Host Research, University College Dublin, Dublin, Ireland.

Background: We aimed to describe the clinical presentation of individuals presenting with prolonged recovery from coronavirus disease 2019 (COVID-19), known as long COVID.

Methods: This was an analysis within a multicenter, prospective cohort study of individuals with a confirmed diagnosis of COVID-19 and persistent symptoms >4 weeks from onset of acute symptoms. We performed a multiple correspondence analysis (MCA) on the most common self-reported symptoms and hierarchical clustering on the results of the MCA to identify symptom clusters. Read More

View Article and Full-Text PDF

[Autonomic Disorders in Trigeminal Autonomic Cephalalgias: An Update].

Hisanori Kowa

Brain Nerve 2022 Mar;74(3):263-270

Department of Neurology, National Hospital Organization Matsue Medical Center.

The term trigeminal autonomic cephalalgias (TACs) was introduced in the 2 edition of the International Classification of Headache Disorders, and has been retained in the 3 edition. TACs include cluster headache, paroxysmal hemicrania, short-lasting unilateral neuralgiform headache attacks, hemicrania continua, and probable trigeminal autonomic cephalalgia. Headaches classified as TACs share clinical features with unilateral headache and usually present with prominent lateralized and ipsilateral cranial parasympathetic autonomic features, including the following: (1) conjunctival injection and/or lacrimation, (2) nasal congestion and/or rhinorrhea, (3) eyelid edema, (4) forehead and facial sweating, (5) miosis and/or ptosis. Read More

View Article and Full-Text PDF